-
Rheumatology Blood and Tissue Collection Study
Official Title The Ohio State University Rheumatology and Immunology BiorepositoryPurpose
The purpose of this study is to collect samples from patients with rheumatic conditions and store them for use in future research studies which will enable a greater understanding of the conditions and how to better treat them.
Could this study be right for you?
Eligibility Criteria:
- 18 or older
- Ability to provide informed consent
- Willingness to participate in a research study
- Patients with autoimmune diseases or other rheumatic or degenerative disorders, or healthy controls.
Exclusion Criteria:
- Inability to provide informed consent
- Self-reported history of fainting during a blood draw
- Incarceration
Age Range
18 years and up -
Hypoparathyroidism-Focused Clinical Trial
Official Title A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Followed by an Open-Label Extension to Evaluate the Safety and Efficacy of Canvuparatide (MBX 2109) in Adult Patients with HypoparathyroidismPurpose
The purpose of this study is to find out how well canvuparatide works and how safe it is when given as an injection once a week to adults with HypoPT. Canvuparatide is designed to replace parathyroid hormone (PTH), which helps control calcium levels in the body. The goal of this study is to see if participants taking canvuparatide can stop using active vitamin D and reduce the amount of calcium supplements they need while still maintaining normal calcium levels in the blood. In this study, you will get either canvuparatide or placebo for the first 26 weeks of this study. A placebo looks like the study drug but does not contain any active ingredient. Researchers use a placebo to see if a study drug works better or is safer than the current standard of care for hypoparathyroidism.
Could this study be right for you?
Eligibility Criteria of Interest
- Documented diagnosis of post-surgical, chronic, genetic, idiopathic, or autoimmune hypoparathyroidism for atleast 12 months
- Taking calcium supplementation
- NO oral or intravenous bisphosphonates within 12 months
- No active cancer within the past 2 years (5 years for parathyroid carcinoma) or receiving current cancer treatment
- Cannot have previously participated in clinical study with canvuparatide (MBX 2109)
- Willing to participate in weekly injections
Age Range
18 years and up -
Understanding Stress and Alcohol Use in College-Aged Women
Official Title Examining the Role of Sensitivity to Uncertain Threat and Alcohol Response in Risk for AUD following Sexual Assault in College WomenPurpose
The purpose of this study is to better understand how stress relates to alcohol use in biological females aged 21-29.
Participation in the study includes three in-person visits and the completion of daily phone surveys across 21 days while wearing a biosensor, which is similar to a Fitbit or smart watch. The first lab visit includes screening and orientation with blood draw, EKG, and sensory tasks. The second and third lab visits include sensory tasks and intravenous alcohol or placebo (a saline solution) administration. Participation in the study occurs over a period of 7 weeks.
Could this study be right for you?
Inclusion Criteria:
-
Biological female
-
21-29 years old
-
At least a high school education
-
Fluency in English
-
Drink alcohol regularly
(partial list of inclusion criteria)
Exclusion Criteria:
-
Current pregnancy
-
Lifetime history of psychosis
(partial list of exclusion criteria)
Age Range
21 - 29 years -
-
Study of Pain Sensitivity and Responses to Alcohol
Official Title Pain Sensitivity, Alcohol-Induced Analgesia, and Heavy Drinking in Individuals with Opioid Use DisorderPurpose
The purpose of this study is to better understand how pain and related emotions change during sobriety and after drinking alcohol.
The length of the study is approximately 4 weeks and will include three on-campus lab visits at Ohio State's Medical Campus. The first lab visit includes screening and orientation with blood draw, EKG, and sensory tasks. The second and third lab visits include sensory tasks and intravenous alcohol or placebo (a saline solution) administration. The total time commitment of the study is approximately 17 hours.
Could this study be right for you?
Inclusion Criteria:
For this study, we are looking for people ages 21–65 who meet one of the following:
- Drink alcohol regularly
- Drink alcohol regularly and use opioids
- Occasionally drink alcohol and use opioids
(partial list of inclusion criteria)
Exclusion Criteria:
- Sensitivity to alcohol
- Current pregnancy
- Current or past diagnosis of mania or psychosis
(partial list of exclusion criteria)
Age Range
21 - 65 years -
The OSU Sleep Study - An Online Parent Training Research Study for Insomnia/Sleep Problems in Young Children with Autism Spectrum Disorder
Official Title A Parent-Mediated Telehealth Intervention for Insomnia in Young Autistic ChildrenPurpose
Insomnia is a common problem for young children with autism spectrum disorder (ASD) and their families. The purpose of this study is to compare the benefits of sleep parent training (SPT) program to a structured parent education program (SPE) for insomnia improvement in young children with autism spectrum disorder.
Could this study be right for you?
You may be eligible if your child:
1. Has a diagnosis of Autism Spectrum Disorder
2. Has significant Sleep Disturbance
3. Is free of a significant health problem
4. Is on stable medication
Age Range
3 - 7 years -
EEG Research Study
Official Title Neural Biomarkers of Sensory Symptoms in AutismPurpose
This research aims to understand how sensory issues, particularly related to hearing, impact children on the autism spectrum. Using a tool called EEG, we study how their brains respond to sounds. Previous research with adults on the spectrum showed that their brains react more slowly to sounds, affecting their ability to pay attention. This protocol investigates if a similar pattern exists in children with autism.
Could this study be right for you?
We are searching for healthy neurotypical boys aged 8-12.
Age Range
8 - 12 years -
Menthol Study
Official Title Impact of Novel vs. Usual Brand Menthol Cigarettes on Abuse LiabilityPurpose
Adults age 21+ are invited to participate in 5 study visits to understand how different menthol cigarettes compare to one another as well as their usual brand of menthol cigarettes.
Participation includes:
· Five study visits at OSU (four visits, ~3 hours each; one final visit, 2 hours) over the course of three weeks, where you'll smoke your usual brand and study cigarette products and complete surveys
· Two weeks of daily phone surveys (~7 minutes per day)
Could this study be right for you?
- currently smoke menthol cigarettes daily
- willing to abstain from nicotine, tobacco and cannabis products for 12 hours before each study visit
- own a smartphone and are willing to complete daily assessments
- able to read, speak and understand English
Age Range
21 years and up -
A Study about how virtual Yoga sessions affect symptoms and quality of life in patients with diabetic gastroparesis
Official Title The Effect of Virtual Yoga Intervention on Symptom Severity and Quality of Life in Patients with Diabetic GastroparesisPurpose
The purpose of this research study is to understand how virtual Yoga sessions conducted 4 days a week for 12 weeks affect digestive symptoms and quality of life in those suffering from gastroparesis due to diabetes mellitus.
Could this study be right for you?
- Able to understand English
- Must have been diagnosed with gastroparesis
- Must have type 1 or type 2 diabetes mellitusAge Range
18 - 65 years -
Clinical Trial Involving Monthly Injections for Osteogenesis Imperfecta (OI)
Official Title A Phase 2, Multi-center, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Safety and Efficacy of AGA2115 in Adults with Type I, III, or IV Osteogenesis Imperfecta (OI)Purpose
The reason for this study is to see if the investigational drug, called AGA2115, can help increase bone mineral density in people with osteogenesis imperfecta. AGA2115 or a placebo drug will be given at the clinic once a month subcutaneously. During this study, changes in bone biomarkers, number of bone fractures, and quality of life, will be measured to see if AGA2115 can help people with osteogenesis imperfecta. This study will also look at how the body absorbs, breaks down and gets rid of AGA2115 (called pharmacokinetics), if AGA2115 affects any markers of bone metabolism in the body, if the body’s natural defense system (the immune system) tries to make antibodies to AGA2115 (called immunogenicity) and how well people feel while taking AGA2115, including any side effects they may have.
You will be asked to complete the following: perform monthly injections, take Vitamin D and Calcium supplements, perform ECGs and DEXA scans, provide blood samples, perform grip strength tests, do hearing tests (called Audiometry and Tympanometry), complete questionnaires, undergo a one-time bone biopsy, and see the study doctor.
If you do not have genetic confirmation of osteogenesis imperfecta, we may be able to test for it through the study.
The study will last 27 months.
Could this study be right for you?
The most important eligibility criteria include the following. This is not an expansive list.
- Genetic confirmation of Osteogenesis Imperfecta Type I, III, or IV diagnosis
- DXA scan assessing L1-L4 region
- BMD T-score <= -1.0 at lumber spine OR total hip OR femoral neck
- Cannot be taking IV or oral bisphosphonate with the past 6 months
Age Range
18 - 75 years -
"Debio-4126" for patients with Acromegaly currently taking octreotide ("Sandostatin" or "Mycapssa") or lanreotide ("Somatuline") with Dr. Luma Ghalib, MD.
Official Title "A Phase 3 randomized 3-arm trial (double-blind Debio 4126, placebo control, and open-label Debio 4126), to assess the efficacy and safety of Debio 4126, a 12-week octreotide formulation, in patients with acromegaly previously treated with somatostatin analogs"Purpose
The purpose of this trial is to see if the study medication "Debio-4126" can safely maintain a low level of growth hormone ("GH") and insulin-like growth factor 1 ("IGF‑1") lab values for patients diagnosed with Acromegaly.
You will be asked to come to visits 1-2 times a month and receive an injection every 12 weeks at our clinic.
At clinic visits, you will be asked to answer questions about your medical history, speak to the study doctor, provide blood and urine samples, do ECGs and other imaging techniques, receive the study medication, and complete questionnaires. Not all of these will be done at every visit. Visits will take place at Outpatient Care East.
This study will use a computer to randomly assign you to the study medication ("Debio-4126") or a placebo, which has no therapeutic effect on the body, commonly referred to as a "sugar pill".
You have 5 chances out of 7 of receiving the study medication.If you are assigned the placebo, you will have a chance to receive the study medication later in the study.
If you are eligible, your participation in this trial will last between 10 to 29 months depending on whether the trial drug is safe and works for you.
If you have any questions about this study, please don't hesitate to reach out to Hangil at 614-814-0809 or email at hangil.kim@osumc.edu.
Could this study be right for you?
Most Important Eligibility Criteria
- Over the age of 18 years old
- Have an official Acromegaly diagnosis
- Currently taking Octreotide or Lanreotide (ex. "Sandostatin", "Mycapssa", "Somatuline", etc...) at any dose for 6 months and on the same dose for the past 3 months.
- Controlled IGF-1 lab values
- Must not have had radiation on pituitary gland in the past
- Must not currently be taking pasireotide (Signifor), pegvisomant (Somavert), or dopamine agonists (Cabergoline)
Age Range
18 - 75 years - Over the age of 18 years old